Navigation Links
Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO
Date:5/16/2011

INDIANAPOLIS, May 16, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from more than 30 studies at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., from June 3 – 7, 2011, including results from PARAMOUNT, a Phase III study of an ALIMTA-based continuation maintenance regimen for the treatment of advanced nonsquamous non-small cell lung cancer.  PARAMOUNT data will be included in the ASCO-sponsored press briefing the morning of June 5 followed by a presentation during the Lung Cancer Oral Abstract Session at ASCO later the same day.

At ASCO, Lilly will present the latest research results on ALIMTA® (pemetrexed for injection) and GEMZAR® (gemcitabine for injection), as well as ERBITUX® (cetuximab) with partners Bristol-Myers Squibb and Merck KGaA.

"Lilly Oncology is committed to exploring innovations that improve outcomes for all people living with cancer," said Richard Gaynor, M.D., vice president, product development and medical affairs for Lilly Oncology.  "We believe that data from PARAMOUNT, and our other studies at ASCO, demonstrate Lilly's focus on tailored therapies, and commitment to addressing unmet needs in cancer care."

ALIMTA Oral Abstract Session:

  • Abstract # CRA7510: Sunday, June 5, 2011, 11:30 - 11:45 AM
    • PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC)
    • Author/Speaker: L. G. Paz-Ares, F. de Marinis, M. Dedui, M. Thomas, J.P. Pujol, P. Bidoli, O. Molinier, T.P. Sahoo, E. Laack, M. Reck, J. Corral, S. Melemed, W. John, N. Chouaki, A. Zimmermann, C. Visseren-Grul, C. Gridelli
    • Location: Hall D1

P-LLY

This press release contains forward-looking statements about the potential of ALIMTA and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that the product will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Oncology to Present New Data on Nine of Its Pipeline Molecules at ASCO 2011
2. Amylin Pharmaceuticals Files Suit Against Eli Lilly
3. Eli Lilly and Company Invests $2.5 Million to Launch The Mind Trusts Grow What Works Campaign
4. U.S. District Court Order Maintains Patent Exclusivity for Lillys Cymbalta
5. Lilly and Medtronic Announce Drug-Device Collaboration for Parkinsons Disease
6. Lilly Declares Second-Quarter 2011 Dividend
7. Lilly Reports First-Quarter 2011 Results
8. Lilly Receives Complete Response Letter From FDA for Liprotamase for the Treatment of Exocrine Pancreatic Insufficiency
9. Avant Healthcare Marketing Receives 2010 Lilly Global Sustained Supplier Award
10. Lilly Confirms Date and Conference Call for First-Quarter 2011 Financial Results Announcement
11. Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
(Date:9/12/2017)...  Consumer reviews on the independent review site Consumer Affairs ... company for hearing aids, ranking it higher than Miracle Ear ... ... For Hearing Aids ... online store that provides high performance, state-of-the-art, German-engineered hearing aids directly ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of ... Philippines. “The Journey: From the Mountains to the Mission Field” is the creation of ... taught all ages and currently teaches a class of ladies at her church, which ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
Breaking Medicine News(10 mins):